{"name":"Azafaros A.G.","slug":"azafaros-ag","ticker":"","exchange":"","domain":"azafarosag.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AZ-3102 (Dose 1)","genericName":"AZ-3102 (Dose 1)","slug":"az-3102-dose-1","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]}],"pipeline":[{"name":"AZ-3102 (Dose 1)","genericName":"AZ-3102 (Dose 1)","slug":"az-3102-dose-1","phase":"phase_3","mechanism":"AZ-3102 is a selective inhibitor of the retinoic acid receptor-related orphan receptor gamma t (RORγt) pathway.","indications":["Moderate to severe plaque psoriasis","Moderate to severe atopic dermatitis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}